alpha-Synuclein promotes IAPP fibril formation in vitro and beta-cell amyloid formation in vivo in miceShow others and affiliations
2020 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 10, no 1, article id 20438Article in journal (Refereed) Published
Abstract [en]
Type 2 diabetes (T2D), alike Parkinson's disease (PD), belongs to the group of protein misfolding diseases (PMDs), which share aggregation of misfolded proteins as a hallmark. Although the major aggregating peptide in beta -cells of T2D patients is Islet Amyloid Polypeptide (IAPP), alpha-synuclein (alpha Syn), the aggregating peptide in substantia nigra neurons of PD patients, is expressed also in beta -cells. Here we show that alpha Syn, encoded by Snca, is a component of amyloid extracted from pancreas of transgenic mice overexpressing human IAPP (denoted hIAPPtg mice) and from islets of T2D individuals. Notably, alpha Syn dose-dependently promoted IAPP fibril formation in vitro and tail-vein injection of alpha Syn in hIAPPtg mice enhanced beta -cell amyloid formation in vivo whereas beta -cell amyloid formation was reduced in hIAPPtg mice on a Snca (-/-) background. Taken together, our findings provide evidence that alpha Syn and IAPP co-aggregate both in vitro and in vivo, suggesting a role for alpha Syn in beta -cell amyloid formation.
Place, publisher, year, edition, pages
Nature Publishing Group, 2020. Vol. 10, no 1, article id 20438
National Category
Biochemistry and Molecular Biology
Identifiers
URN: urn:nbn:se:umu:diva-178308DOI: 10.1038/s41598-020-77409-zISI: 000596280500007PubMedID: 33235246Scopus ID: 2-s2.0-85096611352OAI: oai:DiVA.org:umu-178308DiVA, id: diva2:1515859
2021-01-112021-01-112024-07-02Bibliographically approved